Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer

被引：34
|
作者：
Mao, C. [1 ]
Liao, R-Y [1 ]
Chen, Q. [1 ]
机构：
[1] So Med Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, Guangzhou, Guangdong, Peoples R China
来源：
BRITISH JOURNAL OF CANCER | 2010年 / 102卷 / 05期
关键词：
D O I：
10.1038/sj.bjc.6605575
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：940 / 940
页数：1
相关论文
共 50 条
  • [21] BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
    Chen Mao
    Ru-Yan Liao
    Qing Chen
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 1293 - 1294
  • [22] BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
    Mao, Chen
    Liao, Ru-Yan
    Chen, Qing
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (08) : 1293 - 1294
  • [23] MULTI-DETERMINANTS ANALYSIS OF MOLECULAR ALTERATIONS FOR PREDICTING CLINICAL BENEFIT TO EGFR-TARGETED MONOCLONAL ANTIBODIES IN COLORECTAL CANCER
    Frattini, M. F.
    Sartore-Bianchi, A. S.
    Di Nicolantonio, F. D.
    Nichelatti, M. N.
    Molinari, F. M.
    De Dosso, S. D.
    Saletti, P. S.
    Martini, M. M.
    Cipiani, T. C.
    Marrapese, G. M.
    Mazzucchelli, L. M.
    Lamba, S. L.
    Veronese, S. V.
    Bardelli, A. B.
    Siena, S. S.
    ANNALS OF ONCOLOGY, 2010, 21 : I15 - I15
  • [24] Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
    Sartore-Bianchi, Andrea
    Di Nicolantonio, Federica
    Nichelatti, Michele
    Molinari, Francesca
    De Dosso, Sara
    Saletti, Piercarlo
    Martini, Miriam
    Cipani, Tiziana
    Marrapese, Giovanna
    Mazzucchelli, Luca
    Lamba, Simona
    Veronese, Silvio
    Frattini, Milo
    Bardelli, Alberto
    Siena, Salvatore
    PLOS ONE, 2009, 4 (10):
  • [25] Overcoming resistance to EGFR-targeted therapies in cancer
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (02) : 120 - 120
  • [26] Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
    Sartore-Bianchi, Andrea
    Valtorta, Emanuele
    Amatu, Alessio
    Veronese, Silvio
    Lauricella, Calogero
    Bonazzina, Erica
    Siravegna, Giulia
    Truini, Mauro
    Bardelli, Alberto
    Siena, Salvatore
    ESMO OPEN, 2016, 1 (04)
  • [27] Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
    Parseghian, Christine
    Eluri, Madhulika
    Kopetz, Scott
    Raghav, Kanwal
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [28] The quest to overcome resistance to EGFR-targeted therapies in cancer
    Chong, Curtis R.
    Jaenne, Pasi A.
    NATURE MEDICINE, 2013, 19 (11) : 1389 - 1400
  • [29] Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
    Lorenzato, Annalisa
    Magri, Alessandro
    Matafora, Vittoria
    Audrito, Valentina
    Arcella, Pamela
    Lazzari, Luca
    Montone, Monica
    Lamba, Simona
    Deaglio, Silvia
    Siena, Salvatore
    Bertotti, Andrea
    Trusolino, Livio
    Bachi, Angela
    Di Nicolantonio, Federica
    Bardelli, Alberto
    Arena, Sabrina
    CANCERS, 2020, 12 (03)
  • [30] MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies
    Cappuzzo, Federico
    Sacconi, Andrea
    Landi, Lorenza
    Ludovini, Vienna
    Biagioni, Francesca
    D'Incecco, Armida
    Capodanno, Alessandra
    Salvini, Jessica
    Corgna, Enrichetta
    Cupini, Samanta
    Barbara, Cecilia
    Fontanini, Gabriella
    Crino, Lucio
    Blandino, Giovanni
    CLINICAL COLORECTAL CANCER, 2014, 13 (01) : 37 - U62
12345